These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 2462161)

  • 1. The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various beta-adrenergic blockers.
    Pauwels PJ; Gommeren W; Van Lommen G; Janssen PA; Leysen JE
    Mol Pharmacol; 1988 Dec; 34(6):843-51. PubMed ID: 2462161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereochemical comparison of nebivolol with other beta-blockers.
    Siebert CD; Hänsicke A; Nagel T
    Chirality; 2008 Feb; 20(2):103-9. PubMed ID: 18072266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human beta 1- and beta 2-adrenergic receptor binding and mediated accumulation of cAMP in transfected Chinese hamster ovary cells. Profile of nebivolol and known beta-adrenergic blockers.
    Pauwels PJ; Van Gompel P; Leysen JE
    Biochem Pharmacol; 1991 Oct; 42(9):1683-9. PubMed ID: 1681809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blocker.
    Prisant LM
    J Clin Pharmacol; 2008 Feb; 48(2):225-39. PubMed ID: 18083889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receptor binding profile of tibalosine, a new antihypertensive.
    Chatelain P; Friedhoff AJ; Meller E; Mennini T; Gorissen H; Roba J
    Arzneimittelforschung; 1984; 34(7):754-8. PubMed ID: 6093823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adrenoceptor blocking properties of the stereoisomers of amosulalol (YM-09538) and the corresponding desoxy derivative (YM-11133).
    Honda K; Takenaka T; Miyata-Osawa A; Terai M
    J Pharmacol Exp Ther; 1986 Mar; 236(3):776-83. PubMed ID: 2869143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving mechanisms of action of beta blockers: focus on nebivolol.
    Mason RP; Giles TD; Sowers JR
    J Cardiovasc Pharmacol; 2009 Aug; 54(2):123-8. PubMed ID: 19528811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-adrenoceptor-mediated cAMP accumulation in cardiac cells: effects of nebivolol.
    Pauwels PJ; Leysen JE; Janssen PA
    Eur J Pharmacol; 1989 Dec; 172(6):471-9. PubMed ID: 2575531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol.
    Ignarro LJ
    Cardiovasc Ther; 2008; 26(2):115-34. PubMed ID: 18485134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism.
    Cockcroft JR; Chowienczyk PJ; Brett SE; Chen CP; Dupont AG; Van Nueten L; Wooding SJ; Ritter JM
    J Pharmacol Exp Ther; 1995 Sep; 274(3):1067-71. PubMed ID: 7562470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a new, highly specific, beta 3-adrenergic receptor radioligand, [3H]SB 206606.
    Muzzin P; Boss O; Mathis N; Revelli JP; Giacobino JP; Willcocks K; Badman GT; Cantello BC; Hindley RM; Cawthorne MA
    Mol Pharmacol; 1994 Aug; 46(2):357-63. PubMed ID: 8078497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker.
    Ignarro LJ
    Blood Press Suppl; 2004 Oct; 1():2-16. PubMed ID: 15587107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide.
    Gupta S; Wright HM
    Cardiovasc Ther; 2008; 26(3):189-202. PubMed ID: 18786089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan.
    Leysen JE; Gommeren W; Heylen L; Luyten WH; Van de Weyer I; Vanhoenacker P; Haegeman G; Schotte A; Van Gompel P; Wouters R; Lesage AS
    Mol Pharmacol; 1996 Dec; 50(6):1567-80. PubMed ID: 8967979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta 1-adrenoceptor selectivity of nebivolol and bisoprolol. A comparison of [3H]CGP 12.177 and [125I]iodocyanopindolol binding studies.
    Bundkirchen A; Brixius K; Bölck B; Nguyen Q; Schwinger RH
    Eur J Pharmacol; 2003 Jan; 460(1):19-26. PubMed ID: 12535855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nitric oxide mechanisms of nebivolol.
    Maffei A; Lembo G
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):317-27. PubMed ID: 19443516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No-dependent vasodilation induced by nebivolol in coronary circulation is not mediated by beta-adrenoceptors or by 5 HT1A-receptors.
    Chlopicki S; Kozlovski VI; Gryglewski RJ
    J Physiol Pharmacol; 2002 Dec; 53(4 Pt 1):615-24. PubMed ID: 12512696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding of beta-adrenoceptor antagonists to rat and rabbit lung: special reference to levobunolol.
    Quast U; Vollmer KO
    Arzneimittelforschung; 1984; 34(5):579-84. PubMed ID: 6147147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of the new beta-blockers in treating cardiovascular disease.
    Weber MA
    Am J Hypertens; 2005 Dec; 18(12 Pt 2):169S-176S. PubMed ID: 16373195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigations on the binding properties of the nootropic agent pyroglutamic acid.
    Barone D; Spignoli G
    Drugs Exp Clin Res; 1990; 16(2):85-99. PubMed ID: 1976055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.